Skip to main content

Zoetis Inc.

corporate_fare Company Profile

Zoetis Inc.

ZTS·NYSE·Life Sciences·CIK 0001555280

Zoetis Inc. is a global animal health company that discovers, develops, manufactures, and sells medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. The company operates a diversified business, offering products for eight core species: dogs, cats, and horses (companion animals), and cattle, swine, poultry, fish, and sheep (livestock). Its products fall into seven major categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. Zoetis has a history spanning nearly 75 years, supporting veterinarians, pet owners, and livestock producers globally. The company was incorporated in Delaware in July 2012, having previously operated as a business unit of Pfizer Inc. Its principal executive offices are located at 10 Sylvan Way, Parsippany, New Jersey 07054. The animal health market is segmented by regional customer needs, which vary due to economic, cultural, epidemiological, treatment, environmental, and regulatory factors.

Zoetis Inc. (NYSE:ZTS) is a publicly traded company in the Life Sciences sector. Wiseek monitors ZTS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Zoetis Hit With Class Action Lawsuit Alleging Misrepresentations on Vet Adoption Trends
  • Zoetis Reports Q1 Operational Revenue Decline, Reduced Cash Flow, and $450M IRS Tax Dispute
  • Zoetis Lowers Full-Year 2026 EPS and Revenue Guidance Amid Challenging Market Conditions
  • Zoetis Slashes 2026 EPS Outlook to $6.35-$6.50
  • Zoetis Proxy Details Executive Underperformance, Shareholder Push for Written Consent

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$9.47B
Net Income
$2.67B
Diluted EPS
$6.02
Op. Cash Flow
$2.9B
Free Cash Flow
$2.28B
Gross Profit
$6.8B
Cash & Equivalents
$2.31B
Total Debt
$9.04B
Debt / Equity
2.71×
Net Margin
28.2%
Shares Outstanding
424.93M sh
Source: 10-K · filed 2026-02-12 · accession 0001555280-26-000011
Browse all tickers starting with Z →
$79.23 -0.34% today
52-week range · as of 2026-05-07 $85.31 – $172.23
Market cap
$33.36B
Volume
6.6M (0.7× avg)
3-mo avg 8.8M
Live data · 2026-06-14 06:24 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZTS - Latest Insights

ZTS
Jun 11, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $81.19
Real-time Price: $79.23 info
Change: -$1.96 (-2%) info
Market Cap: $33.358B info
ZTS
May 07, 2026, 4:26 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $87.62
Real-time Price: $79.23 info
Change: -$8.40 (-10%) info
Market Cap: $33.358B info
ZTS
May 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $101.50
Real-time Price: $79.23 info
Change: -$22.27 (-22%) info
Market Cap: $33.358B info
ZTS
May 07, 2026, 7:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $103.00
Real-time Price: $79.23 info
Change: -$23.77 (-23%) info
Market Cap: $33.358B info
ZTS
Apr 08, 2026, 9:01 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $119.50
Real-time Price: $79.23 info
Change: -$40.27 (-34%) info
Market Cap: $33.358B info
ZTS
Feb 12, 2026, 4:49 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $126.33
Real-time Price: $79.23 info
Change: -$47.10 (-37%) info
Market Cap: $33.358B info
ZTS
Feb 12, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $136.73
Real-time Price: $79.23 info
Change: -$57.50 (-42%) info
Market Cap: $33.358B info